0001264931-23-000060.txt : 20231114 0001264931-23-000060.hdr.sgml : 20231114 20231114161643 ACCESSION NUMBER: 0001264931-23-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WORLDS INC CENTRAL INDEX KEY: 0000001961 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 221848316 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24115 FILM NUMBER: 231406544 BUSINESS ADDRESS: STREET 1: 11 ROYAL ROAD CITY: BROOKLINE STATE: MA ZIP: 02445 BUSINESS PHONE: 617-725-8900 MAIL ADDRESS: STREET 1: 11 ROYAL ROAD CITY: BROOKLINE STATE: MA ZIP: 02445 FORMER COMPANY: FORMER CONFORMED NAME: Worlds.com, Inc. DATE OF NAME CHANGE: 20080521 FORMER COMPANY: FORMER CONFORMED NAME: WORLDS COM INC DATE OF NAME CHANGE: 20000519 FORMER COMPANY: FORMER CONFORMED NAME: WORLDS INC DATE OF NAME CHANGE: 19980213 10-Q 1 wdddq32023.htm
false 2023 Q3 --12-31 0000001961 P3Y P6M P3Y 0000001961 2023-01-01 2023-09-30 0000001961 2023-11-14 0000001961 2023-09-30 0000001961 2022-12-31 0000001961 2022-01-01 2022-09-30 0000001961 2023-07-01 2023-09-30 0000001961 2022-07-01 2022-09-30 0000001961 us-gaap:CommonStockMember 2021-12-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000001961 us-gaap:WarrantMember 2021-12-31 0000001961 us-gaap:RetainedEarningsMember 2021-12-31 0000001961 2021-12-31 0000001961 us-gaap:CommonStockMember 2022-03-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000001961 us-gaap:WarrantMember 2022-03-31 0000001961 us-gaap:RetainedEarningsMember 2022-03-31 0000001961 2022-03-31 0000001961 us-gaap:CommonStockMember 2022-06-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000001961 us-gaap:WarrantMember 2022-06-30 0000001961 us-gaap:RetainedEarningsMember 2022-06-30 0000001961 2022-06-30 0000001961 us-gaap:CommonStockMember 2022-12-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000001961 us-gaap:WarrantMember 2022-12-31 0000001961 us-gaap:RetainedEarningsMember 2022-12-31 0000001961 us-gaap:CommonStockMember 2023-03-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000001961 us-gaap:WarrantMember 2023-03-31 0000001961 us-gaap:RetainedEarningsMember 2023-03-31 0000001961 2023-03-31 0000001961 us-gaap:CommonStockMember 2023-06-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000001961 us-gaap:WarrantMember 2023-06-30 0000001961 us-gaap:RetainedEarningsMember 2023-06-30 0000001961 2023-06-30 0000001961 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000001961 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000001961 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000001961 2022-01-01 2022-03-31 0000001961 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000001961 us-gaap:WarrantMember 2022-04-01 2022-06-30 0000001961 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000001961 2022-04-01 2022-06-30 0000001961 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000001961 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000001961 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000001961 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000001961 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000001961 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000001961 2023-01-01 2023-03-31 0000001961 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000001961 us-gaap:WarrantMember 2023-04-01 2023-06-30 0000001961 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000001961 2023-04-01 2023-06-30 0000001961 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000001961 us-gaap:WarrantMember 2023-07-01 2023-09-30 0000001961 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000001961 us-gaap:CommonStockMember 2022-09-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000001961 us-gaap:WarrantMember 2022-09-30 0000001961 us-gaap:RetainedEarningsMember 2022-09-30 0000001961 2022-09-30 0000001961 us-gaap:CommonStockMember 2023-09-30 0000001961 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000001961 us-gaap:WarrantMember 2023-09-30 0000001961 us-gaap:RetainedEarningsMember 2023-09-30 0000001961 us-gaap:AntidilutiveSecuritiesNameDomain 2023-09-30 0000001961 us-gaap:AntidilutiveSecuritiesNameDomain 2022-09-30 0000001961 2001-04-01 0000001961 2018-02-08 2018-02-09 0000001961 srt:OfficerMember 2022-01-01 2022-09-30 0000001961 srt:OfficerMember 2023-01-01 2023-09-30 0000001961 srt:OfficerMember 2023-09-30 0000001961 2022-01-03 0000001961 srt:DirectorMember 2023-01-01 2023-09-30 0000001961 2022-02-16 0000001961 srt:DirectorMember 2022-01-01 2022-09-30 0000001961 srt:DirectorMember 2022-09-30 0000001961 WDDD:Outstanding3Member 2023-09-30 0000001961 WDDD:Outstanding4Member 2023-09-30 0000001961 WDDD:Outstanding5Member 2023-09-30 0000001961 WDDD:Outstanding6Member 2023-09-30 0000001961 WDDD:Outstanding7Member 2023-09-30 0000001961 WDDD:Exercisable3Member 2023-09-30 0000001961 WDDD:Exercisable4Member 2023-09-30 0000001961 WDDD:Exercisable5Member 2023-09-30 0000001961 WDDD:Exercisable6Member 2023-09-30 0000001961 WDDD:Exercisable7Member 2023-09-30 0000001961 2018-08-28 0000001961 WDDD:Additionalbonus1Member 2018-08-28 0000001961 WDDD:Additionalbonus2Member 2018-08-28 0000001961 2018-08-28 2022-08-28 0000001961 2019-08-28 0000001961 2020-08-28 0000001961 2023-04-01 2023-04-30 0000001961 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-09-30 0000001961 srt:OfficerMember 2022-09-30 0000001961 2011-01-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:Y WDDD:Interger

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended September 30, 2023

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to __________________

Commission File number 000-24115

WORLDS INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware 22-1848316
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)

11 Royal Road

Brookline, MA 02445
(Address of Principal Executive Offices)


(617) 725-8900
(Registrant's Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

(Check One):

Large Accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

 

As of November 14, 2023, 57,112,506 shares of the Issuer's Common Stock were outstanding.  

 

   

 

 

 

Worlds Inc.

 

Table of Contents 

    Page
Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022 (audited)     2  
Statements of Operations for the three and nine months ended September 30, 2023 and 2022 (unaudited)     3  
Statements of Stockholders’ Deficit for the nine months ended September 30,  2022 and 2023 (unaudited)     4  
Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)     5  
Condensed Notes to Financial Statements     6  

 

 

 

  1 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

       
Worlds Inc.      
Balance Sheets      
September 30, 2023 and December 31, 2022      
   Unaudited  Audited
   September 30, 2023  December 31, 2022
       
ASSETS:          
Current Assets          
Cash and cash equivalents  $31,088   $7,778 
Total Current Assets   31,088    7,778 
           
Total assets  $31,088   $7,778 
           
           
LIABILITIES AND STOCKHOLDERS' DEFICIT:          
Current Liabilities          
Accounts payable  $797,908   $797,908 
Accrued expenses   1,873,091    1,660,933 
Loan payable related party   27,000       
Notes payable exceeding statute of limitations   773,279    773,279 
Total Current Liabilities   3,471,278    3,232,120 
           
Total Liabilities   3,471,278    3,232,120 
           
Common stock (Par value $0.001 authorized 250,000,000 shares, issued and outstanding 57,112,506 at September 30, 2023 and December 31, 2022   57,113    57,113 
Additional paid in capital   42,335,725    42,335,725 
Common stock-warrants   1,206,913    1,206,913 
Accumulated deficit   (47,039,941)   (46,824,093)
Total stockholders' deficit   (3,440,190)   (3,224,342)
           
Total Liabilities and stockholders' deficit  $31,088   $7,778 
           
The accompanying notes are an integral part of these financial statements

 

 

 

  2 

 

 

               
Worlds Inc.              
Statements of Operations              
For the Nine and Three Months Ended              
For September 30, 2023 and 2022              
               
    Unaudited   Unaudited
    Nine Months Ended September 30   Three Months Ended September 30
    2023  2022   2023  2022
Revenue                      
Revenue                          
                       
Total Revenue                          
                       
Cost and Expenses                      
                       
Cost of Revenue                          
                       
Gross Profit/(Loss)                          
                       
Option expense          821,995           699 
Selling, General & Admin.    72,665    424,826     16,263    47,296 
Salaries and related    161,760    154,083     53,826    52,434 
                       
Operating loss    (234,425)   (1,400,904)    (70,089)   100,429 
                       
Other Income (Expense)                      
Gain on sale of marketable securities    76,839    742,693           136,557 
Interest income          10,617           3,578 
Interest expense    (58,262)   (56,756)    (20,632)   (19,126)
Net Income/(Loss)    (215,848)   (704,350)    (90,721)   20,580 
                       
Weighted Average Loss per share, basic and diluted   $ **     (0.01)   $ **      **  
Weighted Average Common Shares Outstanding, basic and diluted    57,112,506    57,112,506     57,112,506    57,112,506 
                       
**=less than $0.01                      
The accompanying notes are an integral part of these financial statements

 

  3 

 

 

 

                   
Worlds Inc.                  
Statement of Stockholders' Deficit               
For the Nine Months Ended September 30, 2022 and 2023 - Unaudited         
                   
         Additional  Common     Total
   Stock  Stock  Paid-in  Stock  Accumulated  stockholders'
   Shares  Amount  capital  Warrants  Deficit  Deficit
                   
 Balances, December 31, 2021   57,112,506    57,113    41,513,730    1,206,913    (45,788,666)   (3,010,910)
                               
 Fair value of stock options   —            805,392                805,392 
 Imputed interest   —            18,711                18,711 
 Net Loss   —                        (739,753)   (739,753)
                               
 Balances, March 31, 2022   57,112,506    57,113    42,337,833    1,206,913    (46,528,419)   (2,926,560)
                               
 Fair value of stock options   —            15,904                15,904 
 Imputed interest   —            18,919                18,919 
 Net Income   —                        14,823    14,823 
                               
 Balances, June 30, 2022   57,112,506    57,113    42,372,656    1,206,913    (46,513,596)   (2,876,914)
                               
 Fair value of stock options   —            699                699 
 Imputed interest   —            19,126                19,126 
 Net Income   —                        20,580    20,580 
                               
 Balances, September 30, 2022   57,112,506    57,113    42,392,481    1,206,913    (46,493,016)   (2,836,509)
                               
 Balances, December 31, 2022   57,112,506    57,113    42,335,725    1,206,913    (46,824,093)   (3,224,342)
                               
 Net Loss   —                        (29,510)   (29,510)
                               
 Balances. March 31, 2023   57,112,506    57,113    42,335,725    1,206,913    (46,853,603)   (3,253,852)
                               
 Net Loss   —                        (95,617)   (95,617)
                               
 Balances, June 30, 2023   57,112,506    57,113    42,335,725    1,206,913    (46,949,220)   (3,349,469)
                               
 Net Loss   —                        (90,721)   (90,721)
                               
 Balances, September 30, 2023   57,112,506    57,113    42,335,725    1,206,913    (47,039,941)   (3,440,190)
                               
The accompanying notes are an integral part of these financial statements

   

  4 

 

       
Worlds Inc.      
Statements of Cash Flows      
Nine Months Ended September 30, 2023 and 2022      
       
   Unaudited  Unaudited
   9/30/2023  9/30/2022
Cash flows from operating activities:          
Net loss  $(215,848)  $(704,350)
Adjustments to reconcile net loss to net cash used in operating activities          
Fair value of stock options issued for services         821,995 
Realized gain on sale of marketable securities   (76,839)   (742,693)
Imputed interest         56,756 
Changes in assets and liabilities          
Accounts payable and accrued expenses   212,158    (150,205)
Net cash (used in) operating activities:   (80,529)   (718,496)
           
Cash flows from investing activities          
Cash received from sale of marketable securities   76,839    742,693 
Accrued interest receivable - related party         (10,617)
Cash provided by investing activities   76,839    732,076 
           
Cash flows from financing activities          
Loan payable related party, net of repayment   27,000       
Net cash provided by financing activities   27,000       
           
Net increase/(decrease) in cash and cash equivalents   23,310    13,579 
           
Cash and cash equivalents, including restricted, beginning of year   7,778    44,421 
           
Cash and cash equivalents, including restricted, end of period  $31,088   $58,000 
           
Supplemental disclosure of cash flow information:          
Cash paid during the period for:          
Interest  $     $   
Income taxes  $     $   
           
The accompanying notes are an integral part of these financial statements

  

 

  5 

 

 

Worlds Inc.

NOTES TO FINANCIAL STATEMENTS

Nine Months Ended September 30, 2023

(Unaudited)

 

NOTE 1 – GOING CONCERN

 

As reflected in the accompanying financial statements, the Company has a working capital deficiency of $3,440,190 and a stockholder’s deficiency of $3,440,190 and used $80,529 of cash in operations for the nine months ended September 30, 2023. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management believes that the actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern, although no assurance can be given that the Company will be successful. 

 

NOTE 2 – DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES

 

Description of Business

 

On May 16, 2011, the Company transferred, through a spin-off to its then wholly owned subsidiary, Worlds Online Inc. (currently called MariMed Inc.), the majority of its operations and related operational assets. The Company retained its patent portfolio and is looking to expand on its legacy celebrity worlds and its collection of non-fungible tokens.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). The Company has incurred significant losses since its inception and has had minimal revenues from operations. The Company will require substantial additional funds for its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. There can be no assurance that the Company will be able to obtain the substantial additional capital resources to pursue its business plan or that any assumptions relating to its business plan will prove to be accurate. The Company has not been able to generate sufficient revenue or obtain sufficient financing which has had a material adverse effect on the Company, including requiring the Company to reduce operations. As the Company has focused its attention historically on increasing its patent portfolio and enforcing it, and more recently on its expansion of its legacy celebrity worlds and its collection of non-fungible tokens, the Company has been operating at a reduced capacity, with only one employee and using consultants to perform any additional work that may be required.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.  

  6 

 

 

 

 

Cash and Cash Equivalents

 

Cash and cash equivalents include highly liquid money market instruments, which have original maturities of three months or less at the time of purchase. 

 

Revenue Recognition

 

Effective January 1, 2018, the Company adopted ASC 606. There was no impact in adopting ASC 606 as the Company has no revenue at this time. In the second quarter of 2011, the Company spun off its online businesses to MariMed Inc. The Company’s sources of revenue after the spinoff was expected to be from sublicenses of the patented technology by Worlds Online and any revenue that may be generated from enforcing its patents. Commencing in the first half of 2023, the Company expects that its revenues will come from its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. The Company recognizes revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Research and Development Costs

 

Research and development costs are charged to operations as incurred. Research and development costs are $0 and $0 as of September 30, 2023 and 2022, respectively.

  

Property and Equipment

 

Property and equipment are stated at cost. Depreciation is provided on a straight line basis over the estimated useful lives of the assets ranging from three to five years. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Maintenance and repairs are charged to expense in the period incurred.

 

Impairment of Long Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with section 360-10-15 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for disclosures about Impairment or Disposal of Long-Lived Assets. Disclosure requires recognition of impairment of long-lived assets in the event the net book value of such assets exceeds its expected cash flows. If so, it is considered to be impaired and is written down to fair value, which is determined based on either discounted future cash flows or appraised values. The Company adopted the statement on inception. No impairments of these types of assets were recognized during the nine months ended September 30, 2023 and 2022.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance set forth in section 718-10 of the FASB ASC for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service. 

  7 

 Income Taxes

 

The Company accounts for income taxes under Section 740-10-30 of the FASB ASC. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

  

Notes Payable

 

The Company has $773,279 in short term notes outstanding at September 30, 2023 and December 31, 2022. These are old notes payable for which the statute of limitations has passed and therefore the Company does not expect it will ever have to repay those notes.

 

Comprehensive Income (Loss)

 

The Company reports comprehensive income and its components following guidance set forth by section 220-10 of the FASB ASC which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. There were no items of comprehensive income (loss) applicable to the Company during the period covered in the financial statements.

 

Loss Per Share

 

Net loss per common share is computed pursuant to section 260-10-45 of the FASB ASC. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. As of September 30, 2023, there were 17,200,000 options and no warrants outstanding and as of September 30, 2022, there were 22,400,000 options and 4,380,000 warrants outstanding whose effect is anti-dilutive and not included in diluted net loss per share for September 30, 2023 or for September 30, 2022. The options and warrants may dilute future earnings per share.

 

Commitments and Contingencies

 

The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. 

  8 

 

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

 

During 2000 the Company was involved in a lawsuit relating to unpaid consulting services. In April, 2001 a judgment against the Company was rendered for approximately $205,000. As of September 30, 2023, and December 31, 2022 the Company recorded a reserve of $205,000 for this lawsuit, which is included in accrued expenses in the accompanying balance sheets.

 

Risk and Uncertainties

 

The Company is subject to risks common to companies in the technology industries, including, but not limited to, litigation, development of new technological innovations and dependence on key personnel.

 

Off Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

Uncertain Tax Positions

 

The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the year ended December 31, 2022.

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

  9 

 

 

The following are the hierarchical levels of inputs to measure fair value:

 

•   Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.

 

•   Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

•   Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, other receivables, accounts payable & accrued expenses, due to related party, notes payable and notes payables, approximate their fair values because of the short maturity of these instruments. The Company's convertible notes payable are measured at amortized cost.

 

Warrant and option expense was measured by using level 3 valuation.

 

Embedded Conversion Features 

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.

   

  10 

 

 

Recent Accounting Pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

NOTE 3 - NOTES PAYABLE   

 

Notes payable at September 30, 2023 consist of the following:    
Unsecured note payable bearing 8% interest, entire balance of principal and unpaid interest due on demand   $ 124,230  
         
Unsecured note payable bearing 10% interest, entire balance of principal and unpaid interest due on demand   $ 649,049  
Total notes   $ 773,279  
2023   $ 773,279  
2024   $ -0-  
2025   $ -0-  
2026   $ -0-  
2027   $ -0-  
    $ 773,279  

   

The Company recorded interest expense related to the notes payable of $56,756 on the notes during the nine months ended September 30, 2023 and September 30, 2022. 

 

NOTE 4 - EQUITY 

 

All common stock numbers and exercise prices in this Note are reflected on a post reverse split (5 to 1) basis, which reverse split was effectuated on February 9, 2018.

 

As detailed below, during the nine months ended September 30, 2022, the Company issued 15,900,000 options, and in addition, another 900,000 options were re-issued to Directors at a new price and an extended term.

 

As consideration for the IP in the Asset Purchase Agreement between the Company and Mr. Kidrin, Mr. Kidrin was granted 15,000,000 options at an exercise price of $0.07 per share for three years. The Company recorded an option expense of $751,744. The fair market value for Mr. Kidrin’s options was calculated using the Black Scholes method assuming a risk free interest of 1.35%, 0% dividend yield, volatility of 174%, and an exercise price of $0.07 per share with a market price of $0.07 per share at issuance date and an expected life of 3 years. The options vested on January 18, 2022.

 

The active directors of the Company received 300,000 options each on January 3, 2022. The options were for service performed during 2019, 2021 and 2022 which were never issued.  The Company recorded an option expense for these options of $31,807 for the nine months ended September 30, 2022. The fair market value for these options was calculated using the Black Scholes method assuming a risk free interest of 1.37%, 0% dividend yield, volatility of 142%, and an exercise price of $0.05 per share with a market price of $0.05 per share at issuance date and an expected life of 5 years. The options vest six months from the date of grant.

  11 

 

 

 

 

The active directors of the Company had their existing options repriced and the terms extended another 5 years. The total number of options that were repriced on February 16, 2022 was 900,000. The Company recorded an option expense for these options of $38,444 for the nine months ended September 30, 2022. The fair market value for these options was calculated using the Black Scholes method assuming a risk free interest of 1.90%, 0% dividend yield, volatility of 153%, and an exercise price of $0.08 per share with a market price of $0.08 per share at issuance date and an expected life of 5 years. The options are all vested upon date of grant.

 

No options were issued during the nine months ended September 30, 2023. 

 

     
  Stock Options  
  Stock options outstanding and exercisable on September 30, 2023 are as follows  
     
Exercise Price per Share Shares Under Option Remaining Life in Years
Outstanding    
$ 0.07     15,000,000   1.30
$ 0.27     300,000   2.21
$ 0.3     100,000   2.25
$ 0.05     900,000   3.26
$ 0.08     900,000   3.38
Total     17,200,000    
           
Exercisable          
$ 0.07     15,000,000   1.30
$ 0.27     300,000   2.21
$ 0.3     100,000   2.25
$ 0.05     900,000   3.26
$ 0.08     900,000   3.38
Total     17,200,000    

     

  12 

 

  

NOTE 5 - COMMITMENTS AND CONTINGENCIES

 

The Company is committed to an employment agreement with its President and CEO, Thom Kidrin. The agreement, dated as of August 28, 2018, is for five years with a one-year renewal option held by Mr. Kidrin.  Mr. Kidrin agreed to a one year extension of his employment agreement. The agreement provides for a base salary of $200,000, which increases 10% on September 1 of each year; a monthly car allowance of $500; an annual bonus equal to 2.5% of Pre-Tax Income (as defined in the agreement); an additional bonus as follows: $75,000, if Pre-Tax Income for the year is between 150% and 200% of the prior fiscal year’s Pre-Tax Income or (B) $100,000, if Pre-Tax Income for the year is between 201% and 250% of the prior fiscal year’s Pre-Tax Income or (C) $200,000, if Pre-Tax Income for the year is 251% or greater than the prior fiscal year’s Pre-Tax Income, but in no event shall this additional bonus exceed five (5%) percent of Pre-Tax Income for such year; payment of up to $10,000 in life insurance premiums; options to purchase 5 million shares of Worlds Inc. common stock at an exercise price of  $0.25 per share, 2 million of which vested on August 28, 2018, 1.5 million vested on August 28, 2019 and the remaining 1.5 million vested on August 28, 2020 ; a death benefit of at least $2 million dollars; and a payment equal to 2.99 times his base amount (as defined in the agreement) in the event of a Change of Control (as defined in the agreement).  The agreement also provides that Mr. Kidrin can be terminated for cause (as defined in the agreement) and that he is subject to restrictive covenants for 12 months after termination.

 

NOTE 6 - RELATED PARTY TRANSACTIONS

 

During the nine months ended September 30, 2023, Mr. Kidrin the CEO of the Company loaned to the Company $47,000 to cover operating expenses. The Company repaid Mr. Kidrin $20,000 in April of 2023. The Company has accrued $1,506 in interest for the Loan.

 

During the nine months ended September 30, 2022, the Company entered into an asset purchase agreement with Thom Kidrin the CEO of the Company. The Company purchased certain IP which was transferred to Worlds Online Inc., now called MariMed Inc. Mr. Kidrin received the IP as part of a settlement agreement he signed with MariMed Inc. The purchase price was 15 million options to purchase Worlds Inc. common stock at $0.07 per share for three years, the closing market price on the date of the agreement. As a related party transaction, the transaction was approved by the Company’s independent directors.

 

The balance in the accrued expense attributable to related parties is $201,090 and $53,688 at September 30, 2023 and December 31, 2022, respectively.  

 

NOTE 7 – ACCRUED EXPENSES

 

Accrued expenses is comprised of (i) $201,090 owed to related parties, (ii) $205,000 related to a judgment against the Company relating to unpaid consulting services dating back to April of 2001, for which collection has not been sought in two decades so the Company does not expect it will ever have to pay it, (iii) $1,437,650 related to old accruals for which the statute of limitations has passed and therefore the Company does not expect it will ever have to repay those amounts, (iv) $11,571 related to accruals for recurring operating expenses, and (v) $17,780 related to a judgement requiring the Company to reimburse litigation fees.

  13 

 

   

NOTE 8 – SALE OF MARKETABLE SECURITIES

 

When Worlds Inc. spun off Worlds Online Inc. in January 2011, the Company retained 5,936,115 shares of common stock in Worlds Online Inc. (now named MariMed Inc.). Those shares were retained on the books of the Company with a book value of $0.

 

During the nine months ended September 30, 2023 the Company generated net cash of $76,839 from the sale of 200,000 shares of MariMed Inc. common stock. The average price was $0.38 per share. 

 

During the nine months ended September 30, 2022 the Company generated net cash of $742,693 from the sale of 1,100,000 shares of MariMed Inc. common stock. The average price was $0.68 per share. 

 

As of September 30, 2023, the Company still owns approximately 350,000 shares of MariMed Inc. common stock.

 

NOTE 9 – SUBSEQUENT EVENTS

 

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any additional recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements.  

 

  14 

 

 

 

Item 2. Management's Discussions and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

 

When used in this Form 10-Q and in other filings by the Company with the Commission, the words or phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," “hope”, "may," "plan," "predict," "project," "will" or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on any such forward looking statements, each of which speak only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligation to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

 

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different. These factors include, but are not limited to, changes that may occur to general economic and business conditions resulting from changes in political, social and economic conditions (whether or not related to terrorism, war, pandemic, weather, environmental or other factors) in the jurisdictions in which we operate and changes to regulations that pertain to our operations.

 

The following discussion should be read in conjunction with the unaudited financial statements and related notes which are included under Item 1.

 

We do not undertake to update our forward-looking statements or risk factors to reflect future events or circumstances.

 

Overview

 

General

 

On May 16, 2011, we transferred, through a spin-off to our then wholly owned subsidiary, Worlds Online Inc. (currently named MariMed Inc.), the majority of our operations and related operational assets. On January 18, 2022 we entered into an asset purchase agreement with Thom Kidrin, our CEO, for the IP that was transferred over to MariMed Inc. Mr. Kidrin received the IP through a settlement agreement that he reached with MariMed Inc.

 

We will be focused on monetizing our collection of non-fungible tokens and our legacy celebrity virtual reality worlds and on expanding our patent portfolio. 

 

Revenues

 

We generated no revenue during the quarter.

 

Expenses

 

We classify our expenses into two broad groups: 

 

  • Cost of revenues; and
  •  selling, general and administration.

 

  15 

 

 

Liquidity and Capital Resources

 

We have had to limit our operations since mid- 2001 due to a lack of liquidity.  However, we were able to issue equity and convertible debt in the last few years and raise small amounts of capital from time to time that, prior to the spinoff, was used to enable us to begin upgrading our technology, develop new products and actively solicit additional business, and more recently to expand on our legacy celebrity worlds and our collection of non-fungible tokens. 


Although we have been able to generate funds through our sale of shares of MariMed Inc., we continue to pursue additional sources of capital though we have no current arrangements with respect to, or sources of, additional financing at this time and there can be no assurance that any such financing will become available. If we cannot raise additional capital, form an alliance of some nature with another entity, raise more funds through the sale of shares of MariMed Inc., or start to generate sufficient revenues, we may be unable to purchase additional patents or otherwise expand operations through acquisition or otherwise.   

  

RESULTS OF OPERATIONS

 

Our net revenues for each of the nine months ended September 30, 2023 and 2022 were $0.  All the operations were transferred over to Worlds Online Inc. in the spin off and we were unsuccessful in prosecuting our patent infringement. Accordingly, going forward, the Company’s sources of revenue are anticipated to be from the monetizing our collection of non-fungible tokens and our legacy celebrity virtual reality worlds.  We still need to raise a sufficient amount of capital to provide the resources required that would enable us to expand our business.

Three months ended September 30, 2023 compared to three months ended September 30, 2022

 

Selling general and administrative (SG&A) expenses decreased to $16,263 for the three months ended September 30, 2023, from $47,296 for the three months ended September 30, 2022. The decrease of $31,033 is due to a decrease in legal fees related to the patent litigation.

 

Salaries and related increased by $1,392 to $53,826 from $52,434 for the three months ended September 30, 2023, and 2022, respectively. The CEO’s salary is based on the terms of his 2018 employment agreement and he is the Company’s only salaried employee.

 

For the three months ended September 30, 2022, the Company recorded an option expense of $699, representing the expense associated with the options issued during the first quarter of 2022. For the three months ended September 30, 2023, there was no option expense. 

 

For the three months ended September 30, 2023, the Company had an interest expense of $20,632 and for September 30, 2022, the Company had an interest expense of $19,126.

 

For the three months ended September 30, 2022, the Company had interest income of $3,578. For the three months ended September 30, 2023, the Company had no interest income.

        

For the three months ended September 30, 2022, the Company had a gain on sale of marketable securities of $136,557. For the three months ended September 30, 2023, the Company had no gain on sale of marketable securities.  

 

 

  16 

As a result of the foregoing, we realized a net loss of $90,721 for the three months ended September 30, 2023, compared to net income of $20,580 in the three months ended September 30, 2022.  

  

Nine months ended September 30, 2023 compared to nine months ended September 30, 2022

 

Revenue is $0 for the nine months ended September 30, 2023 and 2022. All the operations were transferred over to Worlds Online Inc. in the spin off. The business up to the spin off continued to run in a severely diminished mode due to the lack of liquidity. Post spin off we still need to raise a sufficient amount of capital to provide the resources required that would enable us to continue running the business.

 

Cost of revenues is $0 in the nine months ended September 30, 2023 and 2022.

 

Selling general and administrative (SG&A) expenses decreased by $352,161 from $424,826 to $72,665 for the nine months ended September 30, 2022 and 2023, respectively. The decrease is due to a decrease in legal costs related to the patent infringement litigation cases.  

Salaries and related decreased by $7,677 to $161,760 from $154,083 for the nine months ended September 30, 2023 and 2022, respectively.

 

For the nine months ended September 30, 2022, the Company recorded an option expense of $821,995, the estimated fair value of the options issued in the first quarter of 2022. For the nine months ended September 30, 2023, the Company had no option expense. 

 

For the nine months ended September 30, 2023, the Company had interest expense of $58,262. For the nine months ended September 30, 2022, the Company had interest expense of $56,756.

 

For the nine months ended September 30, 2022, the Company had interest income of $10,617. For the nine months ended September 30, 2023, the Company had no interest income.

 

For the nine months ended September 30, 2023, the Company had a gain on sale of marketable securities of $76,839. For the nine months ended September 30, 2022, the Company had a gain on sale of marketable securities of $742,693.

 

As a result of the foregoing, we realized a net loss of $215,848 for the nine months ended September 30, 2023 compared to a net loss of $704,350 in the nine months ended September 30, 2022.  

  

Liquidity and Capital Resources

 

At September 30, 2023, our cash and cash equivalents were $31,088. The Company raised funds by selling shares of stock that the Company retained in the spin off company MariMed Inc. during the nine months ended September 30, 2023. The Company raised $76,839 from selling shares of MariMed Inc. common stock. The Company used $281,619 in cash to pay for operating expenses during the nine months ended September 30, 2023.

 

At September 30, 2022, our cash and cash equivalents were $58,000. The Company raised funds by selling shares of stock that the Company retained in the spin off company MariMed Inc. during the nine months ended September 30, 2022. The Company raised $742,693 from selling shares of MariMed Inc. common stock. The Company used $718,497 in cash to pay for operating expenses during the nine months ended September 30, 2022.

  17 

 

Historically, primary cash requirements have been used to fund the cost of operations and lawsuits, and patent enforcement, with additional funds having been used in connection with the exploration of new business lines.

 

We hope to raise additional funds to be used for further expansion of our legacy celebrity worlds and collection of non-fungible tokens. No assurances can be given that we will be able to raise any additional funds.  

 

Item 4. Controls And Procedures

 

As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2023.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter covered by this report there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

  18 

 

 

  

PART II OTHER INFORMATION

 

Legal Proceedings

 

None

 

Item 1A. Risk Factors

We are not obligated to disclose our risk factors in this report, however, limited information regarding our risk factors appears in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” under the caption “Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q and in “Item 1A. RISK FACTORS” of our 2022 Annual Report on Form 10-K. There have been no material changes from the risk factors previously disclosed in our 2022 Annual Report on Form 10-K. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the nine months ended September 30, 2023 and 2022 we did not raise any funds through the sale of our equity securities. 

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable. 

Item 5. Other Information 

None.

  19 

 

 

 

 

Item 6. Exhibits

 

  3.1     Certificate of Incorporation (a)
         
  3.2     By-Laws Restated as Amended (b)
         
  31.1     Certification of Chief Executive Officer
         
  31.2     Certification of Chief Financial Officer
         
  32.1     Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
         
  32.2     Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
         
   101. INS*XBRL    Instance Document
         
  101. SCH*XBRL    Taxonomy Extension Schema
         
  101. CAL*XBRL    Taxonomy Extension Calculation Linkbase
         
  101. DEF*XBRL    Taxonomy Extension Definition Linkbase
         
  101. LAB*XBRL    Taxonomy Extension Label Linkbase
         
  101. PRE*XBRL    Taxonomy Extension Presentation Linkbase

 

(a) Filed previously with the Proxy Statement Form DEF 14A on May, 19, 2010, as amended as described in Proxy Statements on Form DEF 14A filed on September 7, 2013 and May 17, 2016, and incorporated herein by reference.
(b) Filed previously with the Proxy Statement Form DEF 14A on May, 19, 2010, and incorporated herein by reference.
  20 

 

 

  

 

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this Report to be signed on its behalf by the undersigned thereto duly authorized.

Date: November 14, 2023

WORLDS INC.

 

By: /s/Thomas Kidrin

Thomas Kidrin

President and CEO

 

By: /s/Christopher Ryan

Christopher Ryan

Chief Financial Officer   

  21 

EX-101.SCH 2 wddd-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SALE OF MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ACCRUED EXPENSES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SALE OF MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 wddd-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 4 wddd-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 5 wddd-20230930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Warrant [Member] Retained Earnings [Member] Class of Warrant or Right [Axis] Antidilutive Securities, Name [Domain] Title of Individual [Axis] Officer [Member] Director [Member] Exercise Price Range [Axis] Outstanding 3 [Member] Outstanding 4 [Member] Outstanding 5 [Member] Outstanding 6 [Member] Outstanding 7 [Member] Exercisable 3 [Member] Exercisable 4 [Member] Exercisable 5 [Member] Exercisable 6 [Member] Exercisable 7 [Member] Legal Entity [Axis] Additional bonus 1 Additional bonus 2 Chief Executive Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS: Current Assets Cash and cash equivalents Total Current Assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT: Current Liabilities Accounts payable Accrued expenses Loan payable related party Notes payable exceeding statute of limitations Total Current Liabilities Total Liabilities Common stock (Par value $0.001 authorized 250,000,000 shares, issued and outstanding 57,112,506 at September 30, 2023 and December 31, 2022 Additional paid in capital Common stock-warrants Accumulated deficit Total stockholders' deficit Total Liabilities and stockholders' deficit Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Revenue Total Revenue Cost and Expenses Cost of Revenue Gross Profit/(Loss) Option expense Selling, General & Admin. Salaries and related Operating loss Other Income (Expense) Gain on sale of marketable securities Interest income Interest expense Net Income/(Loss) Weighted Average Loss per share, basic and diluted Weighted Average Common Shares Outstanding, basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares  Fair value of stock options  Imputed interest  Net Loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities Fair value of stock options issued for services Realized gain on sale of marketable securities Imputed interest Changes in assets and liabilities Accounts payable and accrued expenses Net cash (used in) operating activities: Cash flows from investing activities Cash received from sale of marketable securities Accrued interest receivable - related party Cash provided by investing activities Cash flows from financing activities Loan payable related party, net of repayment Net cash provided by financing activities Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents, including restricted, beginning of year Cash and cash equivalents, including restricted, end of period Supplemental disclosure of cash flow information: Cash paid during the period for: Interest Income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Payables and Accruals [Abstract] ACCRUED EXPENSES Investments, Debt and Equity Securities [Abstract] SALE OF MARKETABLE SECURITIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Description of Business Basis of Presentation Use of Estimates Cash and Cash Equivalents Revenue Recognition Research and Development Costs Property and Equipment Impairment of Long Lived Assets Stock-Based Compensation Income Taxes Notes Payable Comprehensive Income (Loss) Loss Per Share Commitments and Contingencies Risk and Uncertainties Off Balance Sheet Arrangements Uncertain Tax Positions Fair Value of Financial Instruments Embedded Conversion Features Recent Accounting Pronouncements Notes Payable Stock Options Working capital deficiency Stockholders deficiency Used cash in operations Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Reserach and development cost Realized ultimate settlement Short term notes outstanding Outstanding options Outstanding warrants Judgment against company Estimated Litigation Liability Unsecured note payable bearing 8% interest, entire balance of principal and unpaid interest due on demand Unsecured note payable bearing 10% interest, entire balance of principal and unpaid interest due on demand Total 2023 Accured interest on notes Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Remaining life in years Total options outstanding Total options exercisable Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Stock Split Terms Options re-issued to directors Officer options granted Exercise price Years for options Recorded option expense Risk free interest Dividend yield Volatility Market price Option expected life Active directors options Recorded options expense Options expected life Options vest time Term extension for directors Number of Options repriced Options issued Length of contract Renewal terms Extension of employment agreement Base salary Annual percentage increase Car allowance Annual bonus pre-tax income Additional bonus Pre-tax income lower range Pre-tax income higher range Pre-tax income higher range Additional bonus Life insurance premiums Options to purchase Options exercise price Vested shares Vested shares Death benefit Payment based amount Restrictive covenants CEO loan Company repaid Mr, Kidrin Accrued interest on loan Other Accrued Liabilities, Current Other Accrued Liabilities, Noncurrent Owed to related parties Judgment amount Old accrual Accruals for operating expense Reimbursement legal fees Number of reatined shares from spin off Ratined shares value on company books Generated cash of sale Shares sold Average price per share Shares owned by MariMed Assets, Current Assets Liabilities, Current Liabilities Retained Earnings (Accumulated Deficit) Equity, Attributable to Parent Liabilities and Equity Revenues Cost of Revenue Interest Expense Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Pre-Tax Income AdditionalBonusExceed ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber1 EX-101.PRE 6 wddd-20230930_pre.xml XBRL PRESENTATION FILE EX-31.1 7 ex31_1.htm CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER

EXHIBIT 31.1  

Certifications

I, Thomas Kidrin, certify that: 

1. I have reviewed this quarterly report on Form 10-Q of Worlds Inc.;  

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): 

a) all significant deficiencies and material weaknesses in the design or operation of internal control which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 

Date: November 14, 2023

/s/ Thomas Kidrin

Thomas Kidrin

Chief Executive Officer

 

   

 

EX-31.2 8 ex31_2.htm CERTIFICATIONS OF CHIEF FINANCIAL OFFICER

EXHIBIT 31.2  

Certifications

I, Christopher J. Ryan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Worlds Inc.;  

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): 

a) all significant deficiencies and material weaknesses in the design or operation of internal control which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 

Date: November 14, 2023

/s/ Christopher J. Ryan

Christopher J. Ryan

Chief Financial Officer

 

   

 

EX-32.1 9 ex32_1.htm SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Exhibit 32.1

  

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Worlds Inc. (the "Company") on Form 10-Q for the nine months ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas Kidrin, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge: 

 

  (1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)   The information contained in the Report fairly presents, in all material respects, our financial condition and result of operations.

 

  WORLDS INC
  (Registrant)
   
Date: November 14, 2023 By:/s/ Thomas Kidrin
  Thomas Kidrin
  Chief Executive Officer 

 

 

   

 

EX-32.2 10 ex32_2.htm SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

Exhibit 32.2 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Worlds Inc. (the "Company") on Form 10-Q for the nine months ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christopher J. Ryan, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge: 

  (1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)   The information contained in the Report fairly presents, in all material respects, our financial condition and result of operations.

  

  WORLDS INC
  (Registrant)
   
Date: November 14, 2023 By:/s/ Christopher J. Ryan
  Christopher J. Ryan
  Chief Financial Officer

 

   

XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
9 Months Ended
Sep. 30, 2023
Nov. 14, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-24115  
Entity Registrant Name WORLDS INC.  
Entity Central Index Key 0000001961  
Entity Tax Identification Number 22-1848316  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 11 Royal Road  
Entity Address, City or Town Brookline  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02445  
City Area Code 617  
Local Phone Number 725-8900  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   57,112,506
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 31,088 $ 7,778
Total Current Assets 31,088 7,778
Total assets 31,088 7,778
Current Liabilities    
Accounts payable 797,908 797,908
Accrued expenses 1,873,091 1,660,933
Loan payable related party 27,000
Notes payable exceeding statute of limitations 773,279 773,279
Total Current Liabilities 3,471,278 3,232,120
Total Liabilities 3,471,278 3,232,120
Common stock (Par value $0.001 authorized 250,000,000 shares, issued and outstanding 57,112,506 at September 30, 2023 and December 31, 2022 57,113 57,113
Additional paid in capital 42,335,725 42,335,725
Common stock-warrants 1,206,913 1,206,913
Accumulated deficit (47,039,941) (46,824,093)
Total stockholders' deficit (3,440,190) (3,224,342)
Total Liabilities and stockholders' deficit $ 31,088 $ 7,778
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 57,112,506 57,112,506
Common stock, shares outstanding 57,112,506 57,112,506
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue        
Revenue
Total Revenue
Cost and Expenses        
Cost of Revenue
Gross Profit/(Loss)
Option expense 699 821,995
Selling, General & Admin. 16,263 47,296 72,665 424,826
Salaries and related 53,826 52,434 161,760 154,083
Operating loss (70,089) 100,429 (234,425) (1,400,904)
Other Income (Expense)        
Gain on sale of marketable securities 136,557 76,839 742,693
Interest income 3,578 10,617
Interest expense (20,632) (19,126) (58,262) (56,756)
Net Income/(Loss) $ (90,721) $ 20,580 $ (215,848) $ (704,350)
Weighted Average Loss per share, basic and diluted       $ 0.01
Weighted Average Common Shares Outstanding, basic and diluted 57,112,506 57,112,506 57,112,506 57,112,506